Lexi Love Rolls into Action with MISTR to Serve Sexual Health Realness

2 days ago

New Campaign Drops with Drag Star Power, Free PrEP and DoxyPEP Access, and a Promo Code for Behind the Scenes…

Spectral Medical Announces First Quarter and Provides Corporate Update

2 days ago

Tigris Trial Enrollment completedTopline results expected to be released in August 2025Entered into an up to US$10 million Promissory Note…

Cascading Flight Delays and Disruptions Trouble Travelers Ahead of Memorial Day Rush

2 days ago

ST. PETERSBURG, Fl, May 09, 2025 (GLOBE NEWSWIRE) -- Flight delays and disruptions have reached an all-time high due to…

Anika Reports First Quarter 2025 Financial Results

2 days ago

First Quarter 2025 Commercial Channel revenue up 18% Integrity™ Implant System continues sequential growth and is on pace to more…

uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress

2 days ago

~ AMT-130 granted Breakthrough Therapy designation by FDA ~ ~ Initial safety data from third cohort of Phase I/II study…

Rapid Micro Biosystems Reports First Quarter 2025 Financial Results

2 days ago

Reports first quarter 2025 total revenue of $7.2 million, representing 28% growth compared to the first quarter of 2024. Reports…

Onex Reports First Quarter 2025 Results

2 days ago

All amounts in U.S. dollars unless otherwise stated TORONTO, May 09, 2025 (GLOBE NEWSWIRE) -- Onex Corporation (TSX: ONEX) today…

OXB to Present at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

2 days ago

OXB to Present at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) Oxford, UK…

Boundless Bio Reports First Quarter 2025 Financial Results and Business Highlights

2 days ago

Initial proof-of-concept data from the ongoing BBI-355 Phase 1/2 POTENTIATE trial in patients with oncogene-amplified cancers anticipated in the second…

Kymera Therapeutics Announces First Quarter 2025 Financial Results and Provides a Business Update

2 days ago

Completed KT-621 (STAT6) SAD/MAD Phase 1 healthy volunteer trial with data to be reported in June 2025 First patient dosed…

This website uses cookies.